Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis - Wikidata - awgldk - TriplyDB

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

http://www.wikidata.org/entity/Q37172003

about

Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.Recent advances in the diagnosis and management of cardiac amyloidosis.Newer Therapies for Amyloid Cardiomyopathy.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Heart transplantation in cardiac amyloidosis.Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.Long-term biological variation of serum protein electrophoresis M-spike, urine M-spike, and monoclonal serum free light chain quantification: implications for monitoring monoclonal gammopathies.Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.How to manage primary amyloidosis.Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone

P2860

Q26827340-996D2160-AEEE-46CB-83D2-0C4C51C8CE1C Q34091229-5FC7DEA1-FEF0-4845-8D1C-07B238F50F60 Q34353682-52715044-AA05-4C4E-9282-720554066372 Q34448455-808F54DF-80C2-45C2-9436-831EC9073450 Q35103966-B14A98C1-3138-4CF3-B63B-C14F49B7BAD6 Q35750326-73566512-A885-47A2-951F-8F2F5DB68946 Q36137449-4D28520A-BD01-4457-8F04-393A7F7DCA79 Q36163205-85F2C958-DEB4-4989-A49A-A03505183732 Q36308575-F6CD53AF-3F24-44FC-BBF2-9B33F497D67D Q36712121-C61C92D4-D4BF-43AA-82CC-7C0A360F5322 Q36910372-5E8F63ED-FD9F-4BE2-B8FA-C9B65AD6E9B4 Q38171831-DF52422E-24CD-40F8-BB55-3CB021C01A6E Q38920614-C5C28514-E171-44A3-9E42-864F53BA0B99 Q38928383-B9763DC0-F547-4BF7-834F-6575406EE28E Q39172346-DB4AC531-DFC5-4D76-AC2C-47A3B5C7A2D3 Q39932145-2AA0FB03-F7B9-47B0-9442-9F3EE5F3EB96 Q40563598-B539416B-D089-4CA5-8606-7BC6B0047703 Q40973226-8FA1BB09-DE65-4480-9D75-4AA08499012C Q42543905-54389D9C-7DFC-4049-9862-E4CC889C2140 Q44248482-6595BDD6-16A7-4C53-BBAF-76DF74FDB0B0 Q44960748-0ECB3961-DAE2-4F9C-A9A4-5E715E251506 Q46400142-EFFEDBFF-E5CF-42E9-848B-0B59010C4B06 Q47679443-8B0F7EC8-82B7-4423-9B98-A30FEFA46F34 Q47727308-183D2A67-A507-4DCA-97F5-DE61AB4C6C2C Q48334990-E2989C6E-D04B-437B-A8EF-BA1BD07F6A20 Q58136617-50384B5D-AEFA-4D63-A3C0-81F46F61BA69

P2860

Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis

http://www.wikidata.org/entity/Q37172003

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Changes in serum-free light ch ...... therapy in primary amyloidosis

@en

Changes in serum-free light ch ...... herapy in primary amyloidosis.

@nl

type

label

Changes in serum-free light ch ...... therapy in primary amyloidosis

@en

Changes in serum-free light ch ...... herapy in primary amyloidosis.

@nl

prefLabel

Changes in serum-free light ch ...... therapy in primary amyloidosis

@en

Changes in serum-free light ch ...... herapy in primary amyloidosis.

@nl

P1433

Q37172003-CA9A77EB-E07E-4DB2-957D-CF4DF1612D20

P1476

Q37172003-DB6D0DD6-B117-4AC9-9E96-832DA25468CF

P2093

Q37172003-30DA7086-E4E3-475D-95E4-0FEA8BE32FF7

Q37172003-7B3B1CD4-F764-46AD-BA2E-4760282A9F9C

Q37172003-A157F8AA-A26F-4240-A0E9-DFB5D0A06D4E

Q37172003-AA193DB1-C973-4A96-B19B-1A322A62E6AF

Q37172003-EA563144-32A8-4C38-A5F6-609C9310FEA3

P2860

Q37172003-003E2726-7F3D-4555-85D0-082FB19225A0

Q37172003-0F06C831-4FA2-4728-BC78-CC4BD64F8068

Q37172003-1066E8AB-63B2-428F-AF48-FBC7AE6A47DA

Q37172003-1767751E-1550-4B07-8E50-F64C45CDC513

Q37172003-1C3F5F17-C027-4751-B2D3-2AC71C00E734

Q37172003-38F47AE1-E1A8-4FBA-B7CA-585207DB3B36

Q37172003-3B2A04AB-92F9-48A1-B2CA-BD19C1CC3102

Q37172003-405924FD-C728-4FED-8906-3E87BE513449

Q37172003-47DA3C8C-1F07-483E-B9A5-08074C86317C

Q37172003-4B7A61D6-2606-4205-BFFE-7C6FC15A131F

P304

Q37172003-A00F580B-D3E1-4243-8E65-5E16280AC69B

P31

Q37172003-3BC5695B-B764-4B88-9C9C-0255FCA16FC2

P356

Q37172003-6A7ADA13-9C4B-451E-AE32-949203D40718

P433

Q37172003-6F652834-7B58-4A57-B044-54FD946ADA2D

P478

Q37172003-A368B2C2-1CE1-4CC1-8DB8-3FCDAD529FF6

P50

Q37172003-06CF62A4-8275-4547-A8CF-E7B9FDB29856

Q37172003-33E9C35A-73CA-4A20-B8BC-13CCDD74195F

Q37172003-34D424CC-5E31-40CB-AED3-2103BD9204DA

Q37172003-4D61B158-4DA4-439A-9A92-8AC530C37DAD

Q37172003-53F60D24-FE92-441D-9B9C-19BB2787E4A3

Q37172003-5E3ED1FC-E199-4233-9FFB-C64D73DEE941

Q37172003-98BDD85F-2AC8-4540-9863-045E216F3226

P577

Q37172003-81BA9949-D691-4551-AF61-85BE2EA0DC0A

P5875

Q37172003-F91D1191-DA09-4BA2-8F0F-C7C0E1E24D30

P698

Q37172003-C01C2449-758C-49FC-8D44-75D9C211BD2A

P932

Q37172003-9BA36720-DFF3-4136-A44A-D0D164A5E647

P356

P1433

American Journal of Hematology

P1476

Changes in serum-free light ch ...... therapy in primary amyloidosis

@en

P2093

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

Nelson Leung

http://www.w3.org/2001/XMLSchema#string

Shaji K Kumar

http://www.w3.org/2001/XMLSchema#string

Shirshendu Sinha

http://www.w3.org/2001/XMLSchema#string

Tow Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine.

Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.

P304

251-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/AJH.21948

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

86

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

S. Vincent Rajkumar

Suzanne R Hayman

Steven R Zeldenrust

P577

2011-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49842976

http://www.w3.org/2001/XMLSchema#string

P698

21328431

http://www.w3.org/2001/XMLSchema#string

P932

3773466

http://www.w3.org/2001/XMLSchema#string